US Patent Issued to JANSSEN BIOTECH, LEGEND BIOTECH USA on Jan. 13 for "BCMA-targeted CAR-T cell therapy of multiple myeloma" (American, Canadian Inventors)

ALEXANDRIA, Va., Jan. 13 -- United States Patent no. 12,522,645, issued on Jan. 13, was assigned to JANSSEN BIOTECH INC. (Horsham, Pa.) and LEGEND BIOTECH USA INC. (Somerset, N.J.).

"BCMA-targeted CAR-T cell therapy of multiple myeloma" was invented by Enrique Zudaire Ubani (Ambler, Pa.), Xiaohu Fan (Edmonton, Canada), Dong Geng (Somerset, N.J.) and Jordan Mark Schecter (Livingston, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein is a method of treating a subject who has a cancer. At least one dose of chimeric antigen receptor (CAR)-T cells comprising a CAR comprising a polypeptide is administered to the subject. The peptide comprises an extracellular antigen binding domain with at least ...